Beeline Medicines launched with a portfolio of five programs licensed from Bristol Myers Squibb, supported by a $300 million Series A led by Bain Capital. The new company is developing afimetoran, a once-daily oral TLR7/8 inhibitor for lupus, alongside additional assets targeting Treg modulation and other immune pathways. Beeline said afimetoran has clinical proof-of-concept in cutaneous lupus erythematosus and received FDA fast track designation for systemic lupus erythematosus, with a Phase II program expected to conclude in the second half of 2026. The launch reflects how bigger pharma’s portfolio transitions are still seeding new startups, especially in immune-mediated disease where validated targets and fast-tracked clinical programs can compress time to next data milestones.